Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine (CC-486) Maintenance in Higher Risk Elderly MDS Patients
NCT04806906Phase 2Completed
- Sponsor
- Università degli Studi di Firenze
- Start
- Mar 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-486 in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Università degli Studi di Firenze. Primary endpoints: Maintenance or improvement of response to therapy, Safety and tolerability of CC-486 and 1 more. Started Mar 2021; status: completed.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04806906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806906.